These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31035765)

  • 1. Consequences of Hypoacidity Induced by Proton Pump Inhibitors - a Practical Approach.
    Rychlíčková J
    Klin Onkol; 2018; 31(6):409-413. PubMed ID: 31035765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations.
    Koyyada A
    Therapie; 2021; 76(1):13-21. PubMed ID: 32718584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.
    Gay C; Toulet D; Le Corre P
    Hematol Oncol; 2017 Sep; 35(3):259-280. PubMed ID: 27925256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.
    Raoul JL; Moreau-Bachelard C; Gilabert M; Edeline J; Frénel JS
    ESMO Open; 2023 Feb; 8(1):100880. PubMed ID: 36764092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for long-term use of proton-pump inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1998 Nov; 55(21):2268-79. PubMed ID: 9825878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid.
    Martinsen TC; Fossmark R; Waldum HL
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer.
    Sharma M; Holmes HM; Mehta HB; Chen H; Aparasu RR; Shih YT; Giordano SH; Johnson ML
    Cancer; 2019 Apr; 125(7):1155-1162. PubMed ID: 30605231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies.
    Iva J; Filip G; Martin B; Pavel Ž; Jan Č
    Klin Onkol; 2018; 31(5):339-344. PubMed ID: 30541319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.
    Savarino V; Di Mario F; Scarpignato C
    Pharmacol Res; 2009 Mar; 59(3):135-53. PubMed ID: 18977444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.
    van Leeuwen RWF; Jansman FGA; Hunfeld NG; Peric R; Reyners AKL; Imholz ALT; Brouwers JRBJ; Aerts JG; van Gelder T; Mathijssen RHJ
    Clin Pharmacokinet; 2017 Jul; 56(7):683-688. PubMed ID: 28101705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Risk of long-term treatment with proton pump inhibitors].
    Mathieu N
    Rev Prat; 2008 Sep; 58(13):1451-4. PubMed ID: 18924330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events of Proton Pump Inhibitors: Potential Mechanisms.
    Corsonello A; Lattanzio F; Bustacchini S; Garasto S; Cozza A; Schepisi R; Lenci F; Luciani F; Maggio MG; Ticinesi A; Butto V; Tagliaferri S; Corica F
    Curr Drug Metab; 2018; 19(2):142-154. PubMed ID: 29219052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.
    Laine L; Ahnen D; McClain C; Solcia E; Walsh JH
    Aliment Pharmacol Ther; 2000 Jun; 14(6):651-68. PubMed ID: 10848649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.
    Robinson M; Horn J
    Drugs; 2003; 63(24):2739-54. PubMed ID: 14664653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
    Shamliyan TA; Middleton M; Borst C
    Clin Ther; 2017 Feb; 39(2):404-427.e36. PubMed ID: 28189362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term acid inhibition: benefits and harms.
    Tepeš B
    Dig Dis; 2011; 29(5):476-81. PubMed ID: 22095013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
    Čoupková H; Vyzula R
    Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a dark side to long-term proton pump inhibitor therapy?
    Nealis TB; Howden CW
    Am J Ther; 2008; 15(6):536-42. PubMed ID: 19127138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug interaction profiles of proton pump inhibitors.
    Blume H; Donath F; Warnke A; Schug BS
    Drug Saf; 2006; 29(9):769-84. PubMed ID: 16944963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety profile of the proton-pump inhibitors.
    Reilly JP
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S11-7. PubMed ID: 10597119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.